Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Transplantation

Does anemia correction delay kidney allograft dysfunction?

In an era of increased concern about the safety of using erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease, findings from the CAPRIT trial have suggested that ESA administration to correct anemia may slow the progression of kidney allograft dysfunction.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lamb, K. E., Lodhi, S. & Meier-Kriesche, H. U. Long-term renal allograft survival in the United States: a critical reappraisal. Am. J. Transplant. 11, 450–462 (2011).

    Article  CAS  Google Scholar 

  2. Gouva, C., Nikolopoulos, P., Ioannidis, J. P. & Siamopoulos, K. C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 66, 753–760 (2004).

    Article  Google Scholar 

  3. Kuriyama, S. et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77, 176–185 (1997).

    Article  CAS  Google Scholar 

  4. Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).

    Article  Google Scholar 

  5. Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).

    Article  CAS  Google Scholar 

  6. Choukroun, G. et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2011060546.

  7. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9 (Suppl. 3), S1–S155 (2009).

  8. US Department of Health and Human Services. FDA modifies dosing recommendations for erythropoiesis-stimulating agents. U. S. Food and Drug Administration [online], (2011).

  9. Poge, U. et al. MDRD equations for estimation of GFR in renal transplant recipients. Am. J. Transplant. 5, 1306–1311 (2005).

    Article  Google Scholar 

  10. Poggio, E. D. et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am. J. Transplant. 6, 100–108 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Edmund Huang.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, E., Bunnapradist, S. Does anemia correction delay kidney allograft dysfunction?. Nat Rev Nephrol 8, 196–198 (2012). https://doi.org/10.1038/nrneph.2012.39

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2012.39

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing